Evidence map›Paper›PMID 36298629›Full record

ReviewVaccines2022

Delineating the SARS-CoV-2 Induced Interplay between the Host Immune System and the DNA Damage Response Network.

Christina Papanikolaou, Vasiliki Rapti, Dimitris Stellas, Dimitra T Stefanou, Konstantinos Syrigos, George N Pavlakis, Vassilis L Souliotis

Open access · goldAbstract readReview
In one paragraph

Review in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. SARS-CoV-2 and the DNA damage response.The Journal of general virology · 2023
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Christina PapanikolaouInstitute of Chemical Biology, National Hellenic Research Foundation, 11635 Athens, Greece.ORCID 0000-0003-3836-6932
Vasiliki RaptiThird Department of Medicine, Thoracic Diseases General Hospital Sotiria, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Dimitris StellasInstitute of Chemical Biology, National Hellenic Research Foundation, 11635 Athens, Greece.ORCID 0000-0002-7787-3921
Dimitra T StefanouFirst Department of Medicine, Laiko General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Konstantinos SyrigosThird Department of Medicine, Thoracic Diseases General Hospital Sotiria, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
George N PavlakisVaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.ORCID 0000-0002-4027-4036
Vassilis L SouliotisInstitute of Chemical Biology, National Hellenic Research Foundation, 11635 Athens, Greece.ORCID 0000-0002-2945-1329
National and Kapodistrian University of Athens · GRNational Hellenic Research Foundation · GRNational Cancer Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 is an infectious disease caused by the SARS-CoV-2 coronavirus and characterized by an extremely variable disease course, ranging from asymptomatic cases to severe illness. Although all individuals may be infected by SARS-CoV-2, some people, including those of older age and/or with certain health conditions, including cardiovascular disease, diabetes, cancer, and chronic respiratory disease, are at higher risk of getting seriously ill. For cancer patients, there are both direct consequences of the COVID-19 pandemic, including that they are more likely to be infected by SARS-CoV-2 and more prone to develop severe complications, as well as indirect effects, such as delayed cancer diagnosis or treatment and deferred tests. Accumulating data suggest that aberrant SARS-CoV-2 immune response can be attributed to impaired interferon signaling, hyper-inflammation, and delayed adaptive immune responses. Interestingly, the SARS-CoV-2-induced immunological abnormalities, DNA damage induction, generation of micronuclei, and the virus-induced telomere shortening can abnormally activate the DNA damage response (DDR) network that plays a critical role in genome diversity and stability. We present a review of the current literature regarding the molecular mechanisms that are implicated in the abnormal interplay of the immune system and the DDR network, possibly contributing to some of the COVID-19 complications.

Indexed as

aberrant immune responseCOVID-19 pandemicdelayed adaptive immune responsesDNA damage responsehyper-inflammationimpaired interferon signalingSARS-CoV-2 coronavirus

Identifiers

PMID36298629
PMCPMC9610764
OpenAlexW4306969179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.